Celgene Corporation (CELG) - Financial and Strategic SWOT Analysis Review

GlobalData, March 2013, Pages: 55

Summary

Celgene Corporation (Celgene) is a biopharmaceutical company. It carries out the research, development, manufacture, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. The company's product portfolio includes Revlimid (lenalidomide), Vidaza, Thalomid (thalidomide), Abraxane and Istodax. The company also has several products at various stages of development for the treatment of hematological and solid tumor cancers, which include multiple myeloma, myelodysplastic syndromes, non-Hodgkin's lymphoma (NHL), myelofibrosis, chronic lymphocytic leukemia (CLL), small cell lung cancer and prostate cancer.

Celgene Corporation Key Recent Developments

Mar 21, 2013: Celgene And bluebird bio To Collaborate With Center For Cell And Gene Therapy To Advance New And Existing CAR T-cell Programs
Mar 04, 2013: Industry Leaders And Academic Researchers Come Together For Innovative Accelerating Cancer Cures Research Symposium
Jan 24, 2013: Celgene Reports Revenue Of $1.45 Billion In Q4 2012
Oct 25, 2012: Celgene Reports Revenue Of $1.4 Billion In Q3 2012
Oct 03, 2012: Leukemia & Lymphoma Society And Celgene Enter Into Partnership To Accelerate Blood Cancer Therapies

This comprehensive SWOT profile of Celgene Corporation provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

List of Tables
List of Figures
Section 1 - About the Company
Celgene Corporation - Key Facts
Celgene Corporation - Key Employees
Celgene Corporation - Key Employee Biographies
Celgene Corporation - Major Products and Services
Celgene Corporation - Pharmaceutical Pipeline Products Data
Celgene Corporation, Pipeline Products by Therapy Area
Celgene Corporation, Pipeline Products by Development Phase
Celgene Corporation - History
Celgene Corporation - Company Statement
Celgene Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Celgene Corporation - Business Description
Celgene Corporation - Corporate Strategy
Celgene Corporation - SWOT Analysis
SWOT Analysis - Overview
Celgene Corporation - Strengths
Strength - Focus on Research and Development
Strength - Intellectual Property Portfolio
Strength - Alliances & Partnerships
Strength - Sound Profitability Indicators
Celgene Corporation - Weaknesses
Weakness - Litigations and Legal Issues
Weakness - CGMP Negative Opinion
Celgene Corporation - Opportunities
Opportunity - Robust Product Pipeline
Opportunity - Inorganic Growth Drivers
Opportunity - Market Potential: Oncology
Celgene Corporation - Threats
Threat - Highly Competitive Industry
Threat - Stringent Government Regulations
Threat - Uncertainties in R&D
Celgene Corporation - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Celgene Corporation, Recent Deals Summary
Section 5 – Company’s Recent Developments
Celgene Corporation, Recent Developments
Mar 21, 2013: Celgene And bluebird bio To Collaborate With Center For Cell And Gene Therapy To Advance New And Existing CAR T-cell Programs
Mar 04, 2013: Industry Leaders And Academic Researchers Come Together For Innovative Accelerating Cancer Cures Research Symposium
Jan 24, 2013: Celgene Reports Revenue Of $1.45 Billion In Q4 2012
Oct 25, 2012: Celgene Reports Revenue Of $1.4 Billion In Q3 2012
Oct 03, 2012: Leukemia & Lymphoma Society And Celgene Enter Into Partnership To Accelerate Blood Cancer Therapies
Jul 26, 2012: Celgene Reports Revenue Of $1.4 Billion In Q2 2012
Apr 26, 2012: Celgene Reports Revenue Of $1.3 Billion In Q1 2012
Jan 26, 2012: Celgene Reports Revenue Of $1.3 Billion In Q4 2011
Jan 23, 2012: Celgene Elects Richard Barker To Board
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Celgene Corporation, Key Facts
Celgene Corporation, Key Employees
Celgene Corporation, Key Employee Biographies
Celgene Corporation, Major Products and Services
Celgene Corporation, Number of Pipeline Products by Therapy Area
Celgene Corporation, Number of Pipeline Products by Development Stage
Celgene Corporation, Pipeline Products By Therapy Area and Development Phase
Celgene Corporation, History
Celgene Corporation, Other Locations
Celgene Corporation, Subsidiaries
Celgene Corporation, Key Competitors
Celgene Corporation, Ratios based on current share price
Celgene Corporation, Annual Ratios
Celgene Corporation, Interim Ratios
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Celgene Corporation, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Celgene Corporation, Pipeline Products by Therapy Area
Celgene Corporation, Pipeline Products by Development Phase
Celgene Corporation, Performance Chart (2008 - 2012)
Celgene Corporation, Ratio Charts
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Celgene Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Eisai Co., Ltd.
Takeda Pharmaceutical Company Limited
Amgen Inc.
Shire Plc
Pharmaceutical Product Development, Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
Genta Incorporated

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Aerospace and Defense Industry - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• Defense Robotics - Global Strategic Business Report
• The Global UAV Payload Market 2012-2022
• International Military and Government Helicopter Survey